Oxford-based OMass Therapeutics has raised $310 million (€276 million) in a Series C financing to advance its small-molecule ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results